Elliott Statement on Sampo
11.11.2020 10:00:00 EET | Business Wire | Press release
Elliott Advisors (UK) Limited (“Elliott” or “we”), which advises funds that as at the date of this release collectively hold investments equivalent to more than 3% of the share capital of Sampo Oyj (“Sampo” or the “Company”), welcomes Sampo’s decision to begin the disposal of its investment in Nordea Bank Abp (“Nordea”). Elliott believes this announcement will help to highlight the value of Sampo’s insurance assets, particularly IF P&C, and marks a positive first step towards Sampo making the rapid structural simplifications necessary to re-establish its reputation among shareholders. Elliott believes that a value-creation plan that transforms Sampo into a pure-play insurance company would provide much needed focus and strategic clarity for Sampo, while unlocking in excess of EUR 7 billion in value for shareholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110006320/en/
Elliott’s investment in Sampo reflects our conviction in the intrinsic value of IF P&C, which represents the majority of Sampo’s value. In our view, Sampo’s management team has built the best underwriter in the most attractive P&C insurance market in Europe, a remarkable achievement that reflects the track record of Sampo’s current CEO and CFO, both of whom led IF P&C for the past two decades. As a result of its sustainable competitive advantages, IF P&C stands head and shoulders above its insurance peers in terms of COR outperformance and stability, along with attractive growth opportunities, all of which have enabled the company to generate stable, growing dividends. In addition to IF P&C, Sampo’s portfolio of insurance companies includes stakes in Topdanmark AS, Mandatum Life Insurance Co Ltd and the recently announced acquisition of Hastings Group Holdings plc. Outside of insurance, Sampo owns minority stakes in several private equity investments and a significant stake in Nordea, which has materially outperformed the broader banking market over the past decade.
However, Sampo’s structural complexity and a lack of clarity in its longer-term strategic narrative have contributed to a profound and persistent disconnect between the Company’s intrinsic strengths and its market valuation over the past two years. This significant share price underperformance has not been operationally driven, but rather the result of growing divergence between the performance of the wider insurance and banking sectors. Sampo’s share price has suffered due to the weak share price performance of Nordea, which has damaged sentiment in Sampo and has caused a substantial de-rating of Sampo’s insurance assets, which have seen their P/E multiple vs. peers reduce by ~8x since 2017.
Elliott believes that reconstructing Sampo’s equity story now, through full-scale structural simplification, is necessary to allow the market to appropriately value the Company’s industry-leading insurance assets. This pathway would entail the full separation of Sampo’s investment in Nordea and divestment of Sampo’s various private equity investments. A more coherent corporate structure would allow Sampo’s talented management team to provide more focused stewardship of its different assets and alleviate investor uncertainty surrounding Sampo’s strategy. Elliott believes these sensible measures could create in excess of EUR 7 billion of value, thereby restoring market confidence and reinforcing management’s reputation for delivering value-creating outcomes. In Elliott’s view, yesterday’s announcement is a first step on the path to creating more than 35% upside for Sampo shareholders, underscoring the importance of executing these actions expeditiously.
We look forward to Sampo’s continued transformation and to its February 2021 Capital Markets Day. To provide further details on how Sampo can build upon yesterday’s announcement, Elliott is enclosing a presentation with this press release.
About Elliott
Elliott Management Corporation manages approximately $41 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.
Disclaimer
Elliott intends to reviews its investments in the company on a continuing basis and depending upon various factors, including without limitation, the company’s financial position and strategic direction, the outcome of any discussions with the company, overall market conditions, other investment opportunities available to Elliott Management, and the availability of company securities at prices that would make the purchase or sale of company securities desirable, Elliott may from time to time (in the open market or in private transactions, including since the inception of Elliott position) buy, sell, cover, hedge or otherwise change the form or substance of any of its investments (including company securities) to any degree in any manner permitted by law and expressly disclaims any obligation to notify others of any such changes. Elliott also reserves the right to take any actions with respect to its investments in the company as it may deem appropriate.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006320/en/
Contact information
London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
T: +44 (0)20 3009 1475
srajani@elliottadvisors.co.uk
Finland
Mikael Jungner
Kreab
T: +35 850 554 1615
mikael.jungner@kreab.com
Sweden
Christina Rinman
Diplomat Communications
M: +46 709 711 213
christina.rinman@diplomatcom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
